Gavini Elisabetta, Bonferoni Maria C, Rassu Giovanna, Obinu Antonella, Ferrari Franca, Giunchedi Paolo
Department of Chemistry and Pharmacy, University of Sassari, Sassari, Italy.
Department of Drug Sciences, University of Pavia, Pavia, Italy.
Curr Drug Deliv. 2018;15(7):930-940. doi: 10.2174/1567201815666180226121020.
Drug administration to the posterior segment of the eye has many challenges due to the natural barriers and consequent problems of low and unpredictable bioavailability. There is an increasing need for managing severe posterior eye diseases, such as age-related macular degeneration, diabetic retinopathy, etc. Most of these diseases, if left untreated, lead to blindness. Traditional ocular formulations and topical administrations are almost inefficient and the drug delivery to the back of the eye requires direct administrations through intravitreal injections of innovative drug delivery systems. These systems must be easily injectable, able to release the drug for a prolonged period of time (to overcome the problem of repeated administrations) and made of biodegradable/biocompatible polymers. Among these delivery systems, microspheres still have an important role. This overview wants to highlight the use of microspheres as intravitreal systems to overcome the challenges of back of the eye diseases. Studies have shown that microspheres are able to enhance the intravitreal half-life and thus bioavailability of many drugs, protecting them from degradation. Furthermore, personalized therapies can be made by changing the amount of administered microspheres. This review focuses on the materials (polymers) used for the preparation of the microparticulate systems and comparative remarks are made with respect to the use of nanoparticles.
由于天然屏障以及随之而来的生物利用度低且不可预测的问题,向眼后段给药面临诸多挑战。对于诸如年龄相关性黄斑变性、糖尿病视网膜病变等严重的眼后段疾病的治疗需求日益增加。这些疾病大多若不治疗会导致失明。传统的眼部制剂和局部给药几乎无效,而将药物递送至眼后部需要通过玻璃体内注射创新药物递送系统进行直接给药。这些系统必须易于注射,能够长时间释放药物(以克服重复给药的问题),并且由可生物降解/生物相容的聚合物制成。在这些递送系统中,微球仍然发挥着重要作用。本综述旨在强调微球作为玻璃体内给药系统在克服眼后段疾病挑战方面的应用。研究表明,微球能够延长多种药物在玻璃体内的半衰期,从而提高其生物利用度,保护药物不被降解。此外,通过改变微球给药量可实现个性化治疗。本综述聚焦于用于制备微粒系统的材料(聚合物),并就纳米颗粒的应用进行了比较说明。